Research context
- Supports endogenous GH signaling rather than replacing GH.
- Often evaluated through IGF-1 and symptom tracking.
Review before use
- Review baseline labs, sleep apnea, glucose control, and expected monitoring schedule.
- Compare with CJC/ipamorelin options with a clinician.
Evidence notes
- GHRH analog research and clinical use focus on endogenous growth-hormone stimulation under medical review.
- Monitoring commonly centers on IGF-1, sleep apnea risk, glucose, edema, and expected clinical goals.
Cautions
- Hormone-axis protocols require medical supervision.
- Do not use with unexplained symptoms or active malignancy concerns.
Educational reference only. Not medical advice, dosing guidance, or a treatment claim.
